About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Melanoma Clinical Trials in Nashville | 288 Studies

Clinical Trials MelanomaNashville

Melanoma Clinical Trials in Nashville

Find 288 clinical trials for melanoma near Nashville, Tennessee. Connect with research centers in your area.

All Melanoma trials nationwide All trials in Nashville

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 81-100 of 288 trials

TerminatedStudy CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)This study is an open-label Phase 1/2 evaluation of CB-839 in combination with nivolumab in participants with clear cell renal cell carcinoma, melanoma, and non-small cell lung…NCT02771626·Scottsdale, Arizona and 16 others CompletedCD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With NivolumabThis study is a Phase 1-2 open-label dose escalation study of the immuno-activating monoclonal antibody APX005M administered in combination with nivolumab to adult subjects with…NCT03123783·Tucson, Arizona and 22 others

Melanoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedSU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous MelanomaThe purpose of this study is to evaluate how effective Sunitinib works in treating acral lentiginous and mucosal melanoma which has spread beyond the local region.NCT00577382·Boston, Massachusetts and 4 others

Active not recruitingA Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid TumorsTScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived engeneered T cells are engineered to express a T cell…NCT05973487·Scottsdale, Arizona and 20 others

TerminatedElesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma"Elesclomol (STA-4783), N-malonyl-bis (N'-methyl-N'-thiobenzoylhydrazide) is a new chemical entity with a novel structure. STA-4783 induces an oxidative stress response in cells.NCT00522834·Tucson, Arizona and 100 others

TerminatedAurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV MelanomaRATIONALE: Aurora A kinase inhibitor MLN8237 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.NCT01316692·Nashville, Tennessee

CompletedRandomised Study to Compare the Efficacy of AZD6244 vs TMZThe primary purpose of this study is to compare the efficacy of AZD6244 (ARRY-142886) with temozolomide in patients with advanced melanomaNCT00338130·Santa Monica, California and 32 others

Active not recruitingA Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid TumorsThis is a dose-escalation study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of ABBV-927, and to determine the maximum tolerated dose (MTD) or…NCT02988960·Los Angeles, California and 21 others

RecruitingA Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid TumorsKB707-01 is a Phase 1/2, open-label, multicenter, dose escalation and expansion study.NCT05970497·Los Angeles, California and 14 others

CompletedA Safety and Tolerability Study of INCAGN02385 in Select Advanced MalignanciesThe purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.NCT03538028·Los Angeles, California and 3 others

Active not recruitingA Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in…NCT05557045·Los Angeles, California and 14 others

TerminatedA Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV MelanomaThe purpose of this study is to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma.NCT05002569·Birmingham, Alabama and 183 others

CompletedA Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic MelanomaThis open-label, dose-escalation study of vemurafenib in combination with cobimetinib will evaluate the safety, tolerability and pharmacokinetics in participants with BRAFV600…NCT01271803·Los Angeles, California and 9 others

CompletedA Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic MelanomaTo evaluate the efficacy of vemurafenib in combination with cobimetinib (GDC-0973), compared with vemurafenib and placebo, in previously untreated BRAF V600 mutation-positive…NCT01689519·Birmingham, Alabama and 155 others

TerminatedA Phase Ib Study of LXH254-centric Combinations in NSCLC or MelanomaTo characterize safety and tolerability and identify a recommended dose and regimen for the LXH254 in combination with LTT462 or trametinib or ribociclib.NCT02974725·San Diego, California and 31 others

TerminatedSafety Study of MGD009 in B7-H3-expressing TumorsThe purpose of this study is to evaluate the safety of MGD009 when given to patients with B7-H3-expressing tumors.NCT02628535·Los Angeles, California and 19 others

UnknownSafety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced MalignanciesThe primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies…NCT04137900·Birmingham, Alabama and 23 others

Active not recruitingTTX-080 HLA-G Antagonist in Subjects With Advanced CancersTTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy…NCT04485013·Tucson, Arizona and 40 others

CompletedNAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)The NAUTILUS study is a Phase 1b/2, multi-center, open-label study in which patients with activating mutations in the RAS pathway (Phase 1b) and patients with NRAS-mutated…NCT05340621·Phoenix, Arizona and 11 others

TerminatedStudy of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) PathwayThis is a multicenter clinical trial to evaluate DCC-3084 alone or in combination with other cancer therapies in participants with advanced cancers.NCT06287463·Los Angeles, California and 8 others

PreviousPage 5 of 15Next

Other Conditions in Nashville

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Leukemia Lymphoma